Philip J Palumbo1, Jessica M Fogel1, Sarah E Hudelson1, Ethan A Wilson2, Stephen Hart3, Laura Hovind3, Estelle Piwowar-Manning1, Carole Wallis4, Maria A Papathanasopoulos5, Mariza G Morgado6, Shanmugam Saravanan7, Srikanth Tripathy8, Joseph J Eron9, Joel E Gallant10, Marybeth McCauley11, Theresa Gamble12, Mina C Hosseinipour13,14, Nagalingeswaran Kumarasamy15, James G Hakim16, Jose H Pilotto17, Johnstone Kumwenda18, Victor Akelo19, Sheela V Godbole20, Breno R Santos21, Beatriz Grinsztejn22, Ravindre Panchia23, Suwat Chariyalertsak24, Joseph Makhema25, Sharlaa Badal-Faesen26, Ying Q Chen2, Myron S Cohen9, Susan H Eshleman1. 1. Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD. 2. Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA. 3. Frontier Science and Technology Research Foundation, Amherst, NY. 4. Specialty Molecular Division, Lancet Laboratories and BARC-SA, Johannesburg, South Africa. 5. HIV Pathogenesis Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. 6. Laboratory of AIDS and Molecular Immunology, Oswaldo Cruz Institute, Rio de Janeiro, Brazil. 7. Y. R. Gaitonde Centre for AIDS Research and Education, Chennai, India. 8. National Institute for Research in Tuberculosis, Chennai, India. 9. Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC. 10. Department of Specialty Services, Southwest CARE Center, Santa Fe, NM. 11. HPTN Leadership and Operations Center, FHI 360, Washington, DC. 12. HPTN Leadership and Operations Center, FHI 360, Durham, NC. 13. Division of Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, NC. 14. UNC Project-Malawi, Institute for Global Health and Infectious Diseases, Lilongwe, Malawi. 15. CART CRS, YRGCARE Medical Centre, VHS, Chennai, India. 16. Department of Medicine, University of Zimbabwe, Harare, Zimbabwe. 17. Hospital Geral de Nova Iguacu and Laboratorio de AIDS e Imunologia Molecular-IOC/Fiocruz, Rio de Janeiro, Brazil. 18. College of Medicine-Johns Hopkins Project, Blantyre, Malawi. 19. Kenya Medical Research Institute (KEMRI)-Centers for Disease Control (CDC), Kisumu, Kenya. 20. Department of Epidemiology and Biostatistics, National AIDS Research Institute (ICMR), Pune, India. 21. Department of Infectious Diseases, Hospital Nossa Senhora da Conceição, Porto Alegre, Brazil. 22. Instituto Nacional de Infectologia Evandro Chagas-INI-Fiocruz, Rio de Janeiro, Brazil. 23. Perinatal HIV Research Unit, University of the Witwatersrand, Soweto HPTN CRS, Soweto, South Africa. 24. Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand. 25. Botswana-Harvard AIDS Institute Partnership, Gaborone, Botswana. 26. Clinical HIV Research Unit, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa.
Abstract
INTRODUCTION: We evaluated HIV drug resistance in adults who received early vs. delayed antiretroviral therapy (ART) in a multinational trial [HIV Prevention Trials Network (HPTN) 052, enrollment 2005-2010]. In HPTN 052, 1763 index participants were randomized to start ART at a CD4 cell count of 350-550 cells/mm (early ART arm) or <250 cells/mm (delayed ART arm). In May 2011, interim study results showed benefit of early ART, and all participants were offered ART regardless of CD4 cell count; the study ended in 2015. METHODS:Virologic failure was defined as 2 consecutive viral loads >1000 copies/mL >24 weeks after ART initiation. Drug resistance testing was performed for pretreatment (baseline) and failure samples from participants with virologic failure. RESULTS: HIV genotyping results were obtained for 211/249 participants (128 early ART arm and 83 delayed ART arm) with virologic failure. Drug resistance was detected in 4.7% of participants at baseline; 35.5% had new resistance at failure. In univariate analysis, the frequency of new resistance at failure was lower among participants in the early ART arm (compared with delayed ART arm, P = 0.06; compared with delayed ART arm with ART initiation before May 2011, P = 0.032). In multivariate analysis, higher baseline viral load (P = 0.0008) and ART regimen (efavirenz/lamivudine/zidovudine compared with other regimens, P = 0.024) were independently associated with higher risk of new resistance at failure. CONCLUSIONS: In HPTN 052, the frequency of new drug resistance at virologic failure was lower in adults with early ART initiation. The main factor associated with reduced drug resistance with early ART was lower baseline viral load.
RCT Entities:
INTRODUCTION: We evaluated HIV drug resistance in adults who received early vs. delayed antiretroviral therapy (ART) in a multinational trial [HIV Prevention Trials Network (HPTN) 052, enrollment 2005-2010]. In HPTN 052, 1763 index participants were randomized to start ART at a CD4 cell count of 350-550 cells/mm (early ART arm) or <250 cells/mm (delayed ART arm). In May 2011, interim study results showed benefit of early ART, and all participants were offered ART regardless of CD4 cell count; the study ended in 2015. METHODS:Virologic failure was defined as 2 consecutive viral loads >1000 copies/mL >24 weeks after ART initiation. Drug resistance testing was performed for pretreatment (baseline) and failure samples from participants with virologic failure. RESULTS: HIV genotyping results were obtained for 211/249 participants (128 early ART arm and 83 delayed ART arm) with virologic failure. Drug resistance was detected in 4.7% of participants at baseline; 35.5% had new resistance at failure. In univariate analysis, the frequency of new resistance at failure was lower among participants in the early ART arm (compared with delayed ART arm, P = 0.06; compared with delayed ART arm with ART initiation before May 2011, P = 0.032). In multivariate analysis, higher baseline viral load (P = 0.0008) and ART regimen (efavirenz/lamivudine/zidovudine compared with other regimens, P = 0.024) were independently associated with higher risk of new resistance at failure. CONCLUSIONS: In HPTN 052, the frequency of new drug resistance at virologic failure was lower in adults with early ART initiation. The main factor associated with reduced drug resistance with early ART was lower baseline viral load.
Authors: Jessica M Fogel; Lei Wang; Teresa L Parsons; San-San Ou; Estelle Piwowar-Manning; Ying Chen; Victor O Mudhune; Mina C Hosseinipour; Johnstone Kumwenda; James G Hakim; Suwat Chariyalertsak; Ravindre Panchia; Ian Sanne; Nagalingeswaran Kumarasamy; Beatriz Grinsztejn; Joseph Makhema; Jose Pilotto; Breno R Santos; Kenneth H Mayer; Marybeth McCauley; Theresa Gamble; Namandjé N Bumpus; Craig W Hendrix; Myron S Cohen; Susan H Eshleman Journal: J Infect Dis Date: 2013-08-01 Impact factor: 5.226
Authors: A Cozzi-Lepri; A N Phillips; B Clotet; J Kjaer; V Von Wyl; G Kronborg; A Castagna; J R Bogner; J D Lundgren Journal: HIV Med Date: 2011-08-17 Impact factor: 3.180
Authors: Rami Kantor; Laura Smeaton; Saran Vardhanabhuti; Sarah E Hudelson; Carol L Wallis; Srikanth Tripathy; Mariza G Morgado; Shanmugham Saravanan; Pachamuthu Balakrishnan; Marissa Reitsma; Stephen Hart; John W Mellors; Elias Halvas; Beatriz Grinsztejn; Mina C Hosseinipour; Johnstone Kumwenda; Alberto La Rosa; Umesh G Lalloo; Javier R Lama; Mohammed Rassool; Breno R Santos; Khuanchai Supparatpinyo; James Hakim; Timothy Flanigan; Nagalingeswaran Kumarasamy; Thomas B Campbell; Susan H Eshleman Journal: Clin Infect Dis Date: 2015-02-13 Impact factor: 9.079
Authors: Raph L Hamers; Carole L Wallis; Cissy Kityo; Margaret Siwale; Kishor Mandaliya; Francesca Conradie; Mariette E Botes; Maureen Wellington; Akin Osibogun; Kim C E Sigaloff; Immaculate Nankya; Rob Schuurman; Ferdinand W Wit; Wendy S Stevens; Michèle van Vugt; Tobias F Rinke de Wit Journal: Lancet Infect Dis Date: 2011-07-27 Impact factor: 25.071
Authors: Jessica M Fogel; Sarah E Hudelson; San-San Ou; Stephen Hart; Carole Wallis; Mariza G Morgado; Shanmugam Saravanan; Srikanth Tripathy; Laura Hovind; Estelle Piwowar-Manning; Devin Sabin; Marybeth McCauley; Theresa Gamble; Xinyi C Zhang; Joseph J Eron; Joel E Gallant; Johnstone Kumwenda; Joseph Makhema; Nagalingeswaran Kumarasamy; Suwat Chariyalertsak; James Hakim; Sharlaa Badal-Faesen; Victor Akelo; Mina C Hosseinipour; Breno R Santos; Sheela V Godbole; Jose H Pilotto; Beatriz Grinsztejn; Ravindre Panchia; Kenneth H Mayer; Ying Q Chen; Myron S Cohen; Susan H Eshleman Journal: J Acquir Immune Defic Syndr Date: 2016-07-01 Impact factor: 3.731
Authors: Jens D Lundgren; Abdel G Babiker; Fred Gordin; Sean Emery; Birgit Grund; Shweta Sharma; Anchalee Avihingsanon; David A Cooper; Gerd Fätkenheuer; Josep M Llibre; Jean-Michel Molina; Paula Munderi; Mauro Schechter; Robin Wood; Karin L Klingman; Simon Collins; H Clifford Lane; Andrew N Phillips; James D Neaton Journal: N Engl J Med Date: 2015-07-20 Impact factor: 91.245
Authors: Yinfeng Zhang; William Clarke; Mark A Marzinke; Estelle Piwowar-Manning; Geetha Beauchamp; Autumn Breaud; Craig W Hendrix; Gavin A Cloherty; Lynda Emel; Scott Rose; Lisa Hightow-Weidman; Marc Siegel; Steven Shoptaw; Sheldon D Fields; Darrell Wheeler; Susan H Eshleman Journal: Antimicrob Agents Chemother Date: 2017-06-27 Impact factor: 5.191
Authors: Soo-Yon Rhee; Jose Luis Blanco; Michael R Jordan; Jonathan Taylor; Philippe Lemey; Vici Varghese; Raph L Hamers; Silvia Bertagnolio; Tobias F Rinke de Wit; Avelin F Aghokeng; Jan Albert; Radko Avi; Santiago Avila-Rios; Pascal O Bessong; James I Brooks; Charles A B Boucher; Zabrina L Brumme; Michael P Busch; Hermann Bussmann; Marie-Laure Chaix; Bum Sik Chin; Toni T D'Aquin; Cillian F De Gascun; Anne Derache; Diane Descamps; Alaka K Deshpande; Cyrille F Djoko; Susan H Eshleman; Herve Fleury; Pierre Frange; Seiichiro Fujisaki; P Richard Harrigan; Junko Hattori; Africa Holguin; Gillian M Hunt; Hiroshi Ichimura; Pontiano Kaleebu; David Katzenstein; Sasisopin Kiertiburanakul; Jerome H Kim; Sung Soon Kim; Yanpeng Li; Irja Lutsar; Lynn Morris; Nicaise Ndembi; Kee Peng Ng; Ramesh S Paranjape; Martine Peeters; Mario Poljak; Matt A Price; Manon L Ragonnet-Cronin; Gustavo Reyes-Terán; Morgane Rolland; Sunee Sirivichayakul; Davey M Smith; Marcelo A Soares; Vincent V Soriano; Deogratius Ssemwanga; Maja Stanojevic; Mariane A Stefani; Wataru Sugiura; Somnuek Sungkanuparph; Amilcar Tanuri; Kok Keng Tee; Hong-Ha M Truong; David A M C van de Vijver; Nicole Vidal; Chunfu Yang; Rongge Yang; Gonzalo Yebra; John P A Ioannidis; Anne-Mieke Vandamme; Robert W Shafer Journal: PLoS Med Date: 2015-04-07 Impact factor: 11.069
Authors: Anton Reepalu; Dawit A Arimide; Taye T Balcha; Habtamu Yeba; Adinew Zewdu; Patrik Medstrand; Per Björkman Journal: Open Forum Infect Dis Date: 2021-03-06 Impact factor: 3.835
Authors: Davide F Bavaro; Andrea De Vito; Giuseppe Pasculli; Yagai Bouba; Laura Magnasco; Rachele Pincino; Francesco Saladini; Rossana Lattanzio; Romina Corsini; Serena Arima; Maurizio Zazzi; Francesca Incardona; Barbara Rossetti; Antonia Bezenchek; Borghi Vanni; Antonio Di Biagio Journal: J Med Virol Date: 2022-04-09 Impact factor: 20.693
Authors: Silvia Bertagnolio; Lucas Hermans; Michael R Jordan; Santiago Avila-Rios; Collins Iwuji; Anne Derache; Eric Delaporte; Annemarie Wensing; Theresa Aves; A S M Borhan; Alvin Leenus; Neil Parkin; Meg Doherty; Seth Inzaule; Lawrence Mbuagbaw Journal: J Infect Dis Date: 2021-08-02 Impact factor: 5.226